Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
Surescripts connects pharmacies, payers, PBMs, physicians, hospitals, HIEs, and EH...
Surescripts connects pharmacies, payers, PBMs, ...
Alnylam is leading the translation of RNA interference (RNAi) into a whole new cla...
Alnylam is leading the translation of RNA inter...
MTBC is a healthcare information technology company that provides a fully integrat...
MTBC is a healthcare information technology com...
Sonoma Pharmaceuticals is a specialty pharmaceutical company that develops and mar...
Sonoma Pharmaceuticals is a specialty pharmaceu...
Eiger is a late stage biopharmaceutical company focused on the development and com...
Eiger is a late stage biopharmaceutical company...
Fibrocell is a cell and gene therapy company focused on improving the lives of peo...
Fibrocell is a cell and gene therapy company fo...
Nymox Pharmaceutical Corporation specializes in the research and development of th...
Nymox Pharmaceutical Corporation specializes in...
Unum Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Unum Therapeutics is a clinical-stage biopharma...
Join the National Investor Network and get the latest information with your interests in mind.